Developing innovative turbo-charged infectious disease and cancer vaccines for the animal health market using gene based check point inhibitors.
MBFT is a clinical-stage animal health company developing check-point inhibitor (cpi) immunotherapeutic vaccines. CPIs are the fast-growing field in immunotherapy. Using a proprietary platform technology, we are developing multiple innovative immunotherapies for infectious disease and cancer. Markets are projected are to be worth more than $8B. Keiretsu Forum Mid-Atlantic has completed due diligence, the report is available upon request.